| Literature DB >> 34696783 |
Yue Gao1, Hua-Yan Xu2, Ying-Kun Guo2, Xiao-Ling Wen3, Rui Shi1, Yuan Li4, Zhi-Gang Yang5.
Abstract
BACKGROUND: Type 2 diabetes mellitus (T2DM) is a major risk factor for coronary artery disease and myocardial infarction (MI). The interaction of diabetic cardiomyopathy and MI scars on myocardial deformation in T2DM patients is unclear. Therefore, we aimed to evaluate myocardial deformation using cardiac magnetic resonance (CMR) in T2DM patients with previous MI and investigated the influence of myocardial scar on left ventricular (LV) deformation.Entities:
Keywords: Cardiac magnetic resonance; Diabetic cardiomyopathy; Myocardial infarction; Myocardial scar
Mesh:
Substances:
Year: 2021 PMID: 34696783 PMCID: PMC8547068 DOI: 10.1186/s12933-021-01407-2
Source DB: PubMed Journal: Cardiovasc Diabetol ISSN: 1475-2840 Impact factor: 9.951
Fig. 1Flow chart of the study
Fig. 2Measurement of LV global strain and enhanced area in LGE. Cardiac magnetic resonance tissue tracking in short-axis and long-axis two-chamber and four-chamber cine images at end-diastole (A1–3) and end-systole (B1–3). LGE images for quantification of infarct size (A4, B4) the signal intensity of yellow region was five standard deviations above the mean intensity of the normal myocardium (blue circle)
Baseline characteristics of the study cohort
| Normal | T2DM (MI−) | T2DM (MI+) | |
|---|---|---|---|
| Baseline characteristics | |||
| Age, years | 58.53 ± 8.23 | 55.55 ± 11.8 | 61.54 ± 9.11 |
| Male, n (%) | 27 (48.2%) | 48 (30.7%) | 28 (60.8%)§ |
| BMI, kg/m2 | 23.17 ± 3.14 | 23.67 ± 3.06 | 25.32 ± 3.35 |
| Systolic blood pressure, mmHg | 120.19 ± 8.85 | 127.96 ± 13.11 | 123.67 ± 19.27 |
| Diastolic blood pressure, mmHg | 75.73 ± 10.36 | 79.88 ± 9.88 | 77.89 ± 12.76 |
| Heart rate, bpm | 73.28 ± 10.85 | 72.67 ± 15.42 | 73.80 ± 14.60 |
| Cardiovascular risk factors | |||
| Previous/current smoker, n (%) | 9 (15.2%) | 44 (28.3%) | 23 (50.5%)§ |
| Hyperlipidemia | 0 | 29 (18.5%) | 8 (17.4%) |
| Family history of DM | 0 | 32 (20.5%) | 11 (23.9%) |
| Pervious PCI, n (%) | 0 | 0 | 20 (43.5) % |
| Previous CABG, n (%) | 0 | 0 | 1 (2.2%) |
| NYHA functional class, n | |||
| | – | – | 3 (6.5%) |
| | – | – | 27 (58.7%) |
| | – | – | 15 (32.6%) |
| | – | – | 1 (2.2%) |
| Culprit vessel n (%) | |||
| LM | – | – | 0 |
| LAD | – | – | 14 (30.43%) |
| LCx | – | – | 6 (13.0%) |
| RCA | – | – | 14 (30.43%) |
| Metabolic characteristics | |||
| HbA1c, % | 5.46 ± 0.34 | 7.82 ± 0.87 | 8.10 ± 1.32 |
| Fasting plasma glucose, mmol/L | 5.08 ± 0.45 | 8.28 ± 1.23 | 8.78 ± 2.34 |
| eGFR, mL/min/1.73 m2 | 107.23 ± 8.45 | 95.84 ± 9.32 | 79.60 ± 10.45 |
| NT-proBNP | – | – | 874 (204.75–2032.75) |
| Medication, n (%) | |||
| Aspirin, n (%) | – | 17 (6.5%) | 28 (60.8%) |
| ß-blockers, n (%) | – | 0 | 11 (19.6%) |
| ACEI/ARB, n (%) | – | 5 (3.2%) | 16 (34.7%) |
| Diuretics | – | 1 (0.06%) | 13 (28.2%) |
| Calcium-channel blocker | – | 8 (5.1%) | 5 (10.8%) |
| Insulin | – | 36 (23.1%) | 7 (15.2%) |
| Statin, n (%) | – | 6 (3.8%) | 14 (30.4%) |
T2DM type 2 diabetes mellitus, MI myocardial infarct, BMI body mass index, PCI percutaneous transluminal coronary intervention, CAGB coronary artery bypass grafting, NYHA New York Heart Association, HbA1c glycated hemoglobin, eGFR estimated glomerular filtration rate, ACEI angiotensin converting enzyme inhibitor。
§p < 0.017 versus T2DM patients without MI (Bonferroni’s)
CMR findings between normal individuals, T2DM (MI−) group and T2DM (MI+) group
| Normal | T2DM (MI (−)) | T2DM (MI (+)) | |
|---|---|---|---|
| LVEDVi, mL/m2 | 70.75 (63.97–80.18) | 76.49 (67.45–84.18) | 114.56 (80.18–137.75)* |
| LVESVi, mL/m2 | 23.64 (19.16–28.39) | 26.46 (20.92–32.32)* | 72.52 (39.62–102,18)*§ |
| LVSVi, mL/m2 | 47.52 (42.13–53.67) | 48.17 (41.04–54.36) | 39.33 (31.96–46.71)*§ |
| LVCO, L/min | 5.54 (5.00–6,63) | 5.85 (4.56–7.00) | 5.11 (3.95–6.25) |
| LVEF, % | 66.14 (62.85–70.86)) | 64.74 (59.32–69.69) | 38.26 (24.75–55.68)*§ |
| LV mass, g/m2 | 77.61 (68.40–88.32) | 91.86.86 (74.13–111.40) | 127.80 (103.68,156.91) *§ |
| LVGFI, % | 51.56 (48.03–56.06) | 48.99 (44.38–54.33) | 27.37 (18.12–40.02)§ |
| PS, % | |||
| Radial | 35.32 (32.38–40.72) | 32.11 (25.73–38.83) | 14.71 (9.29–22.83)*§ |
| Circumferential | − 20.92 (− 22.67 to (− 18.84)) | − 19.56 (− 21.47 to (− 17.64)) | − 11.11 (− 16.10 to (− 8.68))*§ |
| Longitudinal | − 15.03 (− 16.68 to (− 12.31)) | − 12.24 (− 14.67 to (− 10.08))* | − 7.41 (− 9.95 to (− 4.75)) *§ |
| PSSR, 1/s | |||
| Radial | 2.05 (1.77–2.48) | 1.745 (1.41–2.26) | 0.83 (0.61–1.44)*§ |
| Circumferential | − 1.02 (− 1.15 to (− 0.92)) | − 0.98 (−1.13 to (− 0.86)) | − 0.61 (− 0.81 to (− 0.45))*§ |
| Longitudinal | − 0.75 (− 0.87 to (− 0.67)) | − 0.69 (− 0.86 to (− 0.55)) | − 0.38 (− 0.56 to (0.20))*§ |
| PDSR, 1/s | |||
| Radial | − 2.80 (− 3.22 to (− 2.12)) | − 2.05 (− 2.65 to (− 1.58)) | − 0.83 (− 1.24 to (− 0.51))*§ |
| Circumferential | 1.32 (1.19–1.53) | 1.12 (0.97–1.36)* | 0.65 (0.50–0.93)*§ |
| Longitudinal | 0.93 (0.70–1.11) | 0.79 (0.60–0.97)* | 0.49 (0.33–0.62)* |
| Infarct size, g | – | – | 20.69 (11.69–32.12) |
| Infarct size, g % of LV | – | – | 17.96 (11.07–25.26) |
| Total LV infarct extent (%) | – | – | 17.12 (9.58–27.53) |
| Infarct territory, n (%) | – | ||
| Interventricular septum | – | – | 22 (47.8%) |
| Inferior | – | – | 20 (43.4%) |
| Lateral | – | – | 13 (28.2%) |
| Anterior | – | – | 12 (26.09%) |
Data are presented as median (25th, 75th percentile)
LVEDVi left ventricular end diastolic volume index, LVESVi left ventricular end systolic volume index, LVSVi left ventricular stroke volume index, LVEF left ventricular ejection fraction, LVGFI left ventricular global function index, MI myocardial infarction, PDSR peak diastolic strain rate, PS peak strain, PSSR peak systolic strain rate
*p < 0.017 versus normal group (Bonferroni’s)
§p < 0.017 versus T2DM patients without MI (Bonferroni’s)
Correlation analysis of LV function and global strain parameters with the myocardial infarction parameters
| Total LV infarct extent (%) | Enhanced mass (g % of LV) | Enhanced area (mL %of LV) | ||||
|---|---|---|---|---|---|---|
| r | P | r | P | r | P | |
| LVGFI, % | − 0.533** | < 0.001 | − 0.507** | < 0.001 | − 0.506** | < 0.001 |
| PS, % | ||||||
| Radial | − 0.455** | 0.001 | − 0.437** | 0.002 | − 0.435** | 0.001 |
| Circumferential | 0.538** | < 0.001 | 0.530** | < 0.0001 | 0.533** | .000 |
| Longitudinal | 0.395** | 0.007 | 0.434** | 0.003 | 0.431** | 0.007 |
| PSSR, % | ||||||
| Radial | − 0.353* | 0.016 | − 0.302* | 0.042 | − 0.297* | 0.045 |
| Circumferential | 0.533** | < 0.001 | 0.525** | < 0.001 | 0.528** | < 0.001 |
| Longitudinal | 0.097 | 0.520 | 0.106 | 0.484 | 0.110 | 0.465 |
| PDSR, % | ||||||
| Radial | 0.160 | 0.287 | 0.163 | 0.280 | 0.172 | 0.254 |
| Circumferential | − 0.235 | 0.116 | − 0.220 | 0.141 | − 0.218 | 0.146 |
| Longitudinal | − 0.123 | 0.417 | − 0.083 | 0.586 | − 0.071 | 0.639 |
*p < 0.05
**p < 0.01
Fig. 3The relationship between infraction parameters and LV function, and LV deformation parameters. GPS global peak strain, PSSR peak systolic strain rate, PDSR peak diastolic strain rate, R radial, C circumferential, L longitudinal
Univariable and multivariable linear regression analysis of LV global PS
| Radial PS | Circumferential PS | Longitudinal PS | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariable | Multivariable | Univariable | Multivariable | Univariable | Multivariable | |||||||||
| r | P value | r | P value | r | P value | r | P value | r | P value | r | P value | |||
| Age | − 0.107 | 0.480 | 0.057 | 0.707 | − 0.045 | 0.768 | ||||||||
| Gender | − 0.262 | 0.079 | 0.269 | 0.071 | 0.262 | 0.079 | ||||||||
| NYHA functional class | − 0.400 | 0.006 | − 0.400 | 0.002 | 0.322 | 0.029 | 0.339 | 0.006 | 0.174 | 0.249 | ||||
| BMI | 0.160 | 0.287 | − 0.112 | 0.458 | − 0.060 | 0.693 | ||||||||
| Hyperlipidemia | 0.151 | 0.318 | − 0.200 | 0.182 | − 0.027 | 0.860 | ||||||||
| Smoking | − 0.252 | 0.091 | 0.310 | 0.026 | 0.336 | 0.022 | ||||||||
| Total LV infarct extent (%) | − 0.455 | 0.001 | − 0.446 | 0.001 | 0.538 | < 0.001 | 0.530 | < 0.001 | 0.395 | 0.007 | ||||
| Anterior infarct | − 0.317 | 0.032 | 0.433 | 0.003 | 0.410 | 0.005 | 0.398 | 0.006 | ||||||
Fig. 4CMR-LGE images and 3D pseudo-color images of LV circumferential strain in T2DM(MI+) patients. A1–3: T2DM(MI+) patient with LV anterior wall and interventricular septum infarction, female, 58 years old, left ventricular short axis (A1), end-diastolic 3D pseudo-color image (A2), end-systolic 3D pseudo-color image (A3). B1–3: T2DM(MI+) patient with LV inferior wall infarction, male, 69 years old, left ventricular short axis (B1), end-diastolic 3D pseudo-color image (B2), end-systolic 3D pseudo-color image (B3)
Fig. 5Left ventricular global PS in T2DM(MI+) patients with different area of myocardial infarct involved
Inter- and intra-observer variability of tissue tracking and LGE
| Intra-observer (n = 70) | 95% CI | Inter-observer (n = 70) | 95% CI | |
|---|---|---|---|---|
| PS, % | ||||
| Radial PS (%) | 0.959 | 0.901–0.982 | 0.955 | 0.905–0.979 |
| Circumferential PS (%) | 0.932 | 0.851–0.969 | 0.938 | 0.866–0.972 |
| Longitudinal PS (%) | 0.923 | 0.831–0.965 | 0.883 | 0.745–0.947 |
| PSSR, 1/s | ||||
| Radial | 0.938 | 0.899–0.977 | 0.920 | 0.833–0.962 |
| Circumferential | 0.866 | 0.862–0.968 | 0.915 | 0.823–0.960 |
| Longitudinal | 0.828 | 0.717–0.935 | 0.849 | 0.516–0.948 |
| PDSR, 1/s | ||||
| Radial | 0.952 | 0.871–0.970 | 0.925 | 0.843–0.964 |
| Circumferential | 0.934 | 0.720–0.936 | 0.847 | 0.596–0.934 |
| Longitudinal | 0.864 | 0.641–0.918 | 0.777 | 0.485–0.913 |
| LGE | ||||
| Infarct size, g | 0.895 | 0.790–0.898 | 0.893 | 0.782–0.947 |
| Infarct size, g % of LV | 0.891 | 0.780–0.896 | 0.885 | 0.667–0.923 |
| Total LV infarct extent (%) | 0.827 | 0.544–0.905 | 0.882 | 0.651–0.893 |
LGE late gadolinium enhancement